Stockreport

Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch [Yahoo! Finance]

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF mg once-daily morning injection with a 16-week double-blind period and a composite primary endpoint of Level 2 and Level 3 hypoglycemic events. The company is preparin [Read more]